Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Integrated Treatment for Cocaine and Mood Disorders - 1
ERP-8654 - Integrated Treatment for Cocaine and Mood Disorders
Status: Enrolling
Updated:  1/11/2017
University of Texas Health Sci Cntr Houston
mi
from
Houston, TX
Integrated Treatment for Cocaine and Mood Disorders - 1
ERP-8654 - Integrated Treatment for Cocaine and Mood Disorders
Status: Enrolling
Updated: 1/11/2017
University of Texas Health Sci Cntr Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine - 1
Phase 1, Double-Blind, Placebo-Controlled Multiple Dose Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine
Status: Enrolling
Updated:  1/11/2017
Uniformed Services University of Health Science
mi
from
Bethesda, MD
Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine - 1
Phase 1, Double-Blind, Placebo-Controlled Multiple Dose Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine
Status: Enrolling
Updated: 1/11/2017
Uniformed Services University of Health Science
mi
from
Bethesda, MD
Click here to add this to my saved trials
Serotonin, Impulsivity, and Cocaine Dependence Treatment
Serotonin, Impulsivity, and Cocaine Dependence Treatment
Status: Enrolling
Updated:  1/11/2017
University of Texas Houston Health Science Center
mi
from
Houston, TX
Serotonin, Impulsivity, and Cocaine Dependence Treatment
Serotonin, Impulsivity, and Cocaine Dependence Treatment
Status: Enrolling
Updated: 1/11/2017
University of Texas Houston Health Science Center
mi
from
Houston, TX
Click here to add this to my saved trials
Levetiracetam (Keppra) Tolerability in Cocaine Abusing Methadone-maintained Patients.
Levetiracetam (Keppra) Tolerability and Efficacy in Cocaine Abusing Methadone-maintained Patients.
Status: Enrolling
Updated:  1/11/2017
Va Ct Healthcare System
mi
from
West Haven, CT
Levetiracetam (Keppra) Tolerability in Cocaine Abusing Methadone-maintained Patients.
Levetiracetam (Keppra) Tolerability and Efficacy in Cocaine Abusing Methadone-maintained Patients.
Status: Enrolling
Updated: 1/11/2017
Va Ct Healthcare System
mi
from
West Haven, CT
Click here to add this to my saved trials
Vigabatrin Ph 1 Cocaine Interaction Study
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Intravenous Cocaine and Oral Gamma Vinyl-Gamma-Amino Butyric Acid (VIGABATRIN) Interaction Study
Status: Enrolling
Updated:  1/11/2017
University of Texas Health Science Center
mi
from
San Antonio, TX
Vigabatrin Ph 1 Cocaine Interaction Study
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Intravenous Cocaine and Oral Gamma Vinyl-Gamma-Amino Butyric Acid (VIGABATRIN) Interaction Study
Status: Enrolling
Updated: 1/11/2017
University of Texas Health Science Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Buprenorphine Naltrexone-P1 A-Cocaine
Attenuation of Opioid Effects of Three Different Doses of Sublingual Buprenorphine / Naloxone by Oral Naltrexone in Healthy Volunteers
Status: Enrolling
Updated:  1/11/2017
Drug Dependence Research Center
mi
from
San Fransisco, CA
Buprenorphine Naltrexone-P1 A-Cocaine
Attenuation of Opioid Effects of Three Different Doses of Sublingual Buprenorphine / Naloxone by Oral Naltrexone in Healthy Volunteers
Status: Enrolling
Updated: 1/11/2017
Drug Dependence Research Center
mi
from
San Fransisco, CA
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Mobile, AL
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Wheat Ridge, CO
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Biddeford, ME
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Biddeford, ME
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
St. Louis, MO
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Summit, NJ
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Summit, NJ
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Medford, OR
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Erie, PA
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Erie, PA
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Greenville, SC
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Johnson City, TN
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Johnson City, TN
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
San Antonio, TX
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
mi
from
Spokane, WA
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
M-CPP and Fenfluramine in Cocaine Addicts - 3
To Study Predictive Values of M-CPP and Fenfluramine in Cocaine Addicts
Status: Enrolling
Updated:  1/17/2017
VA Medical Center
mi
from
Brooklyn, NY
M-CPP and Fenfluramine in Cocaine Addicts - 3
To Study Predictive Values of M-CPP and Fenfluramine in Cocaine Addicts
Status: Enrolling
Updated: 1/17/2017
VA Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Metabolic Effects of Cocaine
Elucidating the Role of the Hypothalamic-Pituitary-Adrenal (HPA) Axis in the Mechanisms Underlying Cocaine Dependence
Status: Enrolling
Updated:  1/17/2017
Massachusetts General Hospital
mi
from
Boston, MA
Metabolic Effects of Cocaine
Elucidating the Role of the Hypothalamic-Pituitary-Adrenal (HPA) Axis in the Mechanisms Underlying Cocaine Dependence
Status: Enrolling
Updated: 1/17/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Follow Up on Freestyle Valves in Children
Follow Up on Freestyle Valves for Right Ventricular Outflow Tract Reconstruction in Children
Status: Enrolling
Updated:  1/25/2017
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Follow Up on Freestyle Valves in Children
Follow Up on Freestyle Valves for Right Ventricular Outflow Tract Reconstruction in Children
Status: Enrolling
Updated: 1/25/2017
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects
A Two Part, Phase I, Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects Protocol 201022
Status: Enrolling
Updated:  1/25/2017
GSK Investigational Site
mi
from
Overland Park, KA
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects
A Two Part, Phase I, Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects Protocol 201022
Status: Enrolling
Updated: 1/25/2017
GSK Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated:  1/30/2017
Miller Children's Hospital at Long Beach Memorial Medical Center
mi
from
Long Beach, CA
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated: 1/30/2017
Miller Children's Hospital at Long Beach Memorial Medical Center
mi
from
Long Beach, CA
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated:  1/30/2017
The Children's Hospital University of Colorado
mi
from
Denver, CO
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated: 1/30/2017
The Children's Hospital University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated:  1/30/2017
Chicago Children's CRS
mi
from
Chicago, IL
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated: 1/30/2017
Chicago Children's CRS
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated:  1/30/2017
University of California, UC San Diego CRS
mi
from
La Jolla, CA
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated: 1/30/2017
University of California, UC San Diego CRS
mi
from
La Jolla, CA
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated:  1/30/2017
Rush Univ. Cook County Hosp. Chicago NICHD CRS
mi
from
Chicago, IL
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated: 1/30/2017
Rush Univ. Cook County Hosp. Chicago NICHD CRS
mi
from
Chicago, IL
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Hollywood, FL
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Baltimore, MD
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Charlotte, NC
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Gastonia, NC
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Gastonia, NC
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Easley, SC
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Easley, SC
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Mt. Pleasant, SC
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Seneca, SC
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Seneca, SC
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
McKinney, TX
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
McKinney, TX
Click here to add this to my saved trials
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated:  2/2/2017
GSK Investigational Site
mi
from
Grove City, OH
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD
Status: Enrolling
Updated: 2/2/2017
GSK Investigational Site
mi
from
Grove City, OH
Click here to add this to my saved trials
A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
Status: Enrolling
Updated:  2/14/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
Status: Enrolling
Updated: 2/14/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
Status: Enrolling
Updated:  2/14/2017
Inova Fairfax Hospital
mi
from
Falls Church, VA
A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
Status: Enrolling
Updated: 2/14/2017
Inova Fairfax Hospital
mi
from
Falls Church, VA
Click here to add this to my saved trials
Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease
Effect of Once Daily Oral Vitamin D3 Supplementation on Inspiratory Muscle Strength in Vitamin D3-Deficient COPD Patients
Status: Enrolling
Updated:  2/14/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease
Effect of Once Daily Oral Vitamin D3 Supplementation on Inspiratory Muscle Strength in Vitamin D3-Deficient COPD Patients
Status: Enrolling
Updated: 2/14/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Cough Reflex Sensitivity and Bronchial Hyper-responsiveness
Pilot Studies Evaluating Cough Reflex Sensitivity and Bronchial Hyper-responsiveness: The Road to Cough and Wheeze in Patients With Gastroesophageal Reflux.
Status: Enrolling
Updated:  2/16/2017
Mayo Clinic Florida
mi
from
Jacksonville, FL
Cough Reflex Sensitivity and Bronchial Hyper-responsiveness
Pilot Studies Evaluating Cough Reflex Sensitivity and Bronchial Hyper-responsiveness: The Road to Cough and Wheeze in Patients With Gastroesophageal Reflux.
Status: Enrolling
Updated: 2/16/2017
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Energy Balance and Weight Gain With Ivacaftor Treatment
Energy Balance and Weight Gain With Ivacaftor Treatment of CFTR Gating Mutations
Status: Enrolling
Updated:  2/16/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Energy Balance and Weight Gain With Ivacaftor Treatment
Energy Balance and Weight Gain With Ivacaftor Treatment of CFTR Gating Mutations
Status: Enrolling
Updated: 2/16/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Autonomic Function in Obstructive Sleep Apnea
Autonomic Function in Obstructive Sleep Apnea (OSA)
Status: Enrolling
Updated:  2/23/2017
Vanderbilt University
mi
from
Nashville, TN
Autonomic Function in Obstructive Sleep Apnea
Autonomic Function in Obstructive Sleep Apnea (OSA)
Status: Enrolling
Updated: 2/23/2017
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
High Dose Nimodipine Treatment Adjunct - 1
High Dose Nimodipine Pharmacotherapy Adjunct
Status: Enrolling
Updated:  2/23/2017
Washington DC VA
mi
from
Washington,
High Dose Nimodipine Treatment Adjunct - 1
High Dose Nimodipine Pharmacotherapy Adjunct
Status: Enrolling
Updated: 2/23/2017
Washington DC VA
mi
from
Washington,
Click here to add this to my saved trials
Evaluation of Benztropine for Cocaine Craving - 2
Evaluation of Efficacy of Benztropine for Cocaine Craving
Status: Enrolling
Updated:  2/23/2017
Washington DC VA
mi
from
Washington,
Evaluation of Benztropine for Cocaine Craving - 2
Evaluation of Efficacy of Benztropine for Cocaine Craving
Status: Enrolling
Updated: 2/23/2017
Washington DC VA
mi
from
Washington,
Click here to add this to my saved trials
Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11
Methylphenidate Raclopride PET Test
Status: Enrolling
Updated:  2/23/2017
New York MDRU
mi
from
New York, NY
Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11
Methylphenidate Raclopride PET Test
Status: Enrolling
Updated: 2/23/2017
New York MDRU
mi
from
New York, NY
Click here to add this to my saved trials
Sleep Apnea Video Education for CPAP (SAVE-CPAP)
Impact of a Short Educational Video on OSA Patient Satisfaction, Knowledge and Outcomes
Status: Enrolling
Updated:  3/2/2017
University of Chicago
mi
from
Chicago, IL
Sleep Apnea Video Education for CPAP (SAVE-CPAP)
Impact of a Short Educational Video on OSA Patient Satisfaction, Knowledge and Outcomes
Status: Enrolling
Updated: 3/2/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Aerosol Inhalation Treatment for Dyspnea
Aerosol Inhalation Treatment for Dyspnea
Status: Enrolling
Updated:  3/6/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Aerosol Inhalation Treatment for Dyspnea
Aerosol Inhalation Treatment for Dyspnea
Status: Enrolling
Updated: 3/6/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Staccato Loxapine Pulmonary Safety in Patients With COPD
Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  3/13/2017
Spartanburg Medical Research
mi
from
Spartanburg, SC
Staccato Loxapine Pulmonary Safety in Patients With COPD
Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 3/13/2017
Spartanburg Medical Research
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Adipose Derived Cells for Chronic Obstructive Pulmonary Disease
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  3/15/2017
US Stem Cell Clinic
mi
from
Sunrise, FL
Adipose Derived Cells for Chronic Obstructive Pulmonary Disease
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 3/15/2017
US Stem Cell Clinic
mi
from
Sunrise, FL
Click here to add this to my saved trials